Vinay K. Puduvalli, M.D.

Peer-Reviewed Articles

1. Hsi, AH, Wathoo, C, Campbell, E, Nassif, M, Buchold, G, Nguyen, LH, McNeill, LH, Hawk, E, Puduvalli, VK, Kamiya Matsuoka, C. Social vulnerability and survival among patients with high-grade glioma treated at a tertiary cancer center. Journal of neuro-oncology 179(1), 2026. e-Pub 2026. PMID: 42530702.
2. Kienhöfer, M, Chi, X, Bhat, S, Campbell, E, Wathoo, C, Gubbiotti, M, Perni, S, Puduvalli, VK, Lin, R, Majd, NK. Genomic determinants of radiation necrosis in diffuse glioma patients. Journal of Clinical Oncology 44:2053, 2026. e-Pub 2026.
3. Ha J, Wang Y, Ma Y, Wu A, Dong S, Jeong SD, Edwards JL, Chang M, Chang YT, Wang X, Dufilho M, Najarro Torres M, McCabe S, Deng W, Grippin AJ, Weinberg JS, Raza SM, DeMonte F, McCutcheon IE, Prabhu S, Ferguson SD, Ene CI, Akdemir K, Basu S, Jindal S, Schrank BR, Hu J, Goswami S, Puduvalli VK, Lang FF, Huntoon K, Sharma P, Kim BYS, Jiang W. Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. Nat Commun 17(1), 2026. e-Pub 2026. PMID: 41803138.
4. Zhang, S, Ozer, BH, Omuro, A, Yuan, Y, Mendoza, TR, Wall, K, Grajkowska, E, Vera, E, Reyes, J, Aldape, KD, Penas-Prado, M, Wu, J, Burton, E, Walbert, T, Mikkelsen, T, Weathers, S, O'Brien, BJ, de Groot, JF, Puduvalli, VK, DeAngelis, LM, Pentsova, E, Kaley, T, Gavrilovic, IT, Gerstner, E, Armstrong, TS, Gilbert, MR. CERN 09-02. Neuro-Oncology Advances 8(1), 2026. e-Pub 2026. PMID: 42016022.
5. Sanchez, JR, Liu, C, Pawar, V, Huang, Y, Diaz-Rohena, DY, Singh, J, Koppikar, P, Lai, TH, St John, L, Puduvalli, VK, Molldrem, JJ, Thandapani, P, Jain, N, Lapalombella, R, Sampath, D. NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. Leukemia and Lymphoma 67(1):97-107, 2026. e-Pub 2026. PMID: 41401031.
6. Msherghi A, Wong F, Xu G, Mawlawi O, Elhadi M, Alsharedi M, Salim HA, Alizada S, Ray WJ, Puduvalli VK, Wintermark M. (18)F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control Study. J Nucl Med 66(12):1883-1890, 2025. e-Pub 2025. PMID: 41101978.
7. Goethe, E, Alfattal, R, Srinivasan, S, Dasgupta, P, Puduvalli, VK, Weathers, S, Ballester, L, Weinberg, J, Prabhu, SS, Ferguson, SD, Gubbiotti, M. High-grade glioma with pleomorphic and pseudopapillary features. Acta Neuropathologica Communications 13(1), 2025. e-Pub 2025. PMID: 40826136.
8. Yeboa DN, Whitfield BT, Lin R, Ejezie CL, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J, McGovern SL, Harrison R, Majd NK, Puduvalli VK, Aaroe AE, Loghin M, O'Brien BJ, Patel AD, Patel CB, Wefel JS, Taslicay CA, Gule-Monroe M, Paulino AC, McAleer MF, Grosshans DR, Ghia AJ, Jiang W, Chung C, Maor M, Yang CH, Gubbiotti MA, Kamiya-Matsuoka C, Ballester LY, Weathers SP, Huse JT. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intensification, margin reduction and epigenetic stratified outcomes with radiation therapy and chemotherapy. J Neurooncol 176(1):72, 2025. e-Pub 2025. PMID: 41191157.
9. Garcia, CR, Highsmith, KN, Knight, SR, Andrade, IP, Leung, CH, Puduvalli, VK, Kamiya Matsuoka, C. Single center experience of IDH inhibitors in recurrent high-grade gliomas. Journal of neuro-oncology 175(2):837-844, 2025. e-Pub 2025. PMID: 40748516.
10. Morad G, Damania AV, Melendez B, Singh BB, Veguilla FJ, Soto RA, Hoballah YM, Sahasrabhojane PV, Wong MC, Ahmed MM, Rico RN, Lewis KN, Wani K, Shamsutdinova DD, Lazcano Segura RN, Ingram DR, Goethe EA, Day A, Flores II, McDaniel LK, Chelvanambi M, Johnson SB, Dimitriou F, Gupta P, Oberai S, Zal MA, Doss P, Jamal MA, Hayase E, Wathoo C, Norberg LM, Jenkins SL, Nass S, Gumin J, Long L, Yang J, Bradley GR, Bekal MP, Dono AG, Pichardo-Rojas PS, Andrewes SW, Ballester LY, Losh JS, Liang J, Huo L, Nielsen DC, Parker Kerrigan BC, Brastianos PK, Fowlkes NW, Chang CC, Jenq RR, Gomez-Manzano C, Huse JT, Davies MA, Lazar AJ, Bhat KP, Tandon N, Esquenazi Y, Peterson CB, Puduvalli VK, Lang FF, Johnston CD, Bullman S, Ajami NJ, Ferguson SD, Wargo JA. Microbial signals in primary and metastatic brain tumors. Nat Med 31(11):3675-3688, 2025. e-Pub 2025. PMID: 41238915.
11. Dasgupta P, Dagher SA, Chi X, Soomro Z, Bhat S, Campbell E, Wintermark M, Puduvalli VK, Lin R, Chen MM, Majd NK. Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype. J Neurooncol 176(1):19, 2025. e-Pub 2025. PMID: 41099968.
12. Ling AL, Gantchev J, Prabhu MC, Basu S, Ahn R, D'Souza A, Masud N, Ball A, Nikas O, Villa GR, Regan MS, Baquer G, Ayoub G, Whittaker CA, Abou-Mrad Z, Santos A, Couturier CP, Elharouni D, Vogelzang J, Yu KKH, Chen H, He Z, Jiang W, Lucas CH, Sax HE, Lang FF, Puduvalli VK, Tabar V, W Brennan C, Boire A, Holdhoff M, Bettegowda C, Cima M, Solomon IH, Yuan Y, Tak PP, Sharma P, White FM, Ligon KL, Agar NYR, Reardon DA, Oliveira G, Chiocca EA. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Sci Transl Med 17(819):eadv2881, 2025. e-Pub 2025. PMID: 41061048.
13. Fleming JL, Pugh SL, Chang SM, McElroy JP, Becker AP, Aldape KD, Shih HA, Ashby LS, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Puduvalli VK, Robins HI, Werner-Wasik M, Mehta M, Chakravarti A. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys 123(1):84-92, 2025. e-Pub 2025. PMID: 40164352.
14. Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, Couturier C, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D, Puduvalli VK, Huse J, Beroukhim R, Kim BYS, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Chiocca EA, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nat Commun 16(1):3957, 2025. e-Pub 2025. PMID: 40295505.
15. Strauss JD, Gilbert MR, Mehta M, Li A, Zhou R, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Stieber VW, Puduvalli VK, Choi S, Martinez NL, Robins HI, Hunter GK, Lin CF, Guedes VA, Richard MA, Pugh SL, Armstrong TS, Scheurer ME. Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825. Neuro Oncol 27(3):767-778, 2025. e-Pub 2025. PMID: 39549280.
16. Rehman S, Ikram M, Khan A, Khan A, Farzia, Khan R, Sinnokrot MO, Puduvalli VK, Jadoon A. Triethylammonium Salts of Dicoumarol: Synthesis, Characterization, Human Antiglioblastoma, Antimicrobial and Antioxidant Studies. Cell Biochem Biophys 83(1):999-1008, 2025. e-Pub 2025. PMID: 39306823.
17. Freitas-Cortez MA, Masrorpour F, Jiang H, Mahmud I, Lu Y, Huang A, Duong LK, Wang Q, Voss TA, Kettlun Leyton CS, Wei B, Chan WK, Lin K, Zhang J, Tsouko E, Ganjoo S, Barsoumian HB, Riad TS, Hu Y, Leuschner C, Puebla-Osorio N, Wang J, Hu J, Davies MA, Puduvalli VK, Billon C, Burris TP, Lorenzi PL, Gan B, Welsh JW. Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins. Mol Cancer 24(1):40, 2025. e-Pub 2025. PMID: 39901247.
18. Lim-Fat MJ, Wen PY, Touat M, Puduvalli VK, Iorgulescu JB. MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma. Neuro Oncol 26(12):2388-2390, 2024. e-Pub 2024. PMID: 39277807.
19. Sharma, P, Xu, J, Puduvalli, VK. Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682123.
20. Sharma, P, Xu, J, Puduvalli, VK. Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682123.
21. Rixe O, Villano JL, Wesolowski R, Noonan AM, Puduvalli VK, Wise-Draper TM, Curry R 3rd, Yilmaz E, Cruze C, Ogretmen B, Tapolsky G, Takigiku R. A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas. Clin Cancer Res 30(22):5053-5060, 2024. e-Pub 2024. PMID: 39264252.
22. Sharma P, Puduvalli VK. Protocol for real-time assessment of mitochondrial and glycolytic ATP production in patient-derived glioma stem-like cells. STAR Protoc 5(3):103159, 2024. e-Pub 2024. PMID: 38941182.
23. Gregory, TA, Knight, SR, Aaroe, AE, Highsmith, KN, Janatpour, ZC, O’Brien, BJ, Majd, NK, Loghin, ME, Patel, C, Weathers, S, Puduvalli, VK, Kamiya Matsuoka, C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma. Neuro-Oncology Practice 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
24. Gregory, TA, Knight, SR, Aaroe, AE, Highsmith, KN, Janatpour, ZC, O’Brien, BJ, Majd, NK, Loghin, ME, Patel, C, Weathers, S, Puduvalli, VK, Kamiya Matsuoka, C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma. Neuro-Oncology Practice 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
25. Shatara M, Blue M, Stanek J, Liu YA, Prevedello DM, Giglio P, Puduvalli VK, Gardner SL, Allen JC, Wong KK, Nelson MD, Gilles FH, Adams RH, Pauly J, O'Halloran K, Margol AS, Dhall G, Finlay JL. Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors. Neurooncol Pract 11(2):188-198, 2024. e-Pub 2024. PMID: 38496907.
26. Majd, NK, Yeboa, DN, Wang, S, Weathers, S, Yuan, Y, Al Anssari, H, Kamiya Matsuoka, C, O'Brien, BJ, Aaroe, AE, Patel, C, Dagher, SA, Wintermark, M, Ferguson, SD, Puduvalli, VK, Liu, SJ, Raleigh, D, de Groot, JF. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. Journal of Clinical Oncology 42(16_suppl):2076, 2024. e-Pub 2024.
27. Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Puduvalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, West BL, Wong ET, Zhang C, Colman H. Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Neurooncol Adv 6(1):vdae202, 2024. e-Pub 2024. PMID: 39734810.
28. Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D, Puduvalli VK, Huse J, Beroukhim R, Kim YSB, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Antonio Chiocca E, Ligon KL, White FM, Sharma P, Tabar V, Agar NYR. Investigative needle core biopsies for multi-omics in Glioblastoma. medRxiv, 2023. e-Pub 2023. PMID: 38234840.
29. Bartkowiak T, Brockman AA, Mobley BC, Harmsen H, Moots P, Merrell R, Johnson DB, Thompson RC, Puduvalli VK, Ihrie RA. Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastoma. medRxiv, 2023. e-Pub 2023. PMID: 38234786.
30. Zhong S, Yang W, Zhang Z, Xie Y, Pan L, Ren J, Ren F, Li Y, Xie H, Chen H, Deng D, Lu J, Li H, Wu B, Chen Y, Peng F, Puduvalli VK, Sai K, Li Y, Cheng Y, Mou Y. Association between viral infections and glioma risk: a two-sample bidirectional Mendelian randomization analysis. BMC Med 21(1):487, 2023. e-Pub 2023. PMID: 38053181.
31. Harrison, R, Majd, NK, Johnson, MO, Urbauer, D, Puduvalli, VK, Khasraw, M. Characterization of industry relationships in oncology. Cancer 129(18):2848-2855, 2023. e-Pub 2023. PMID: 37227811.
32. Khan A, Ikram M, Rehman S, Khan R, Puduvalli VK, Jadoon A, Khan M, Alasmari F, AlAsmari AF. Triethylammonium salt of a synthesized dicoumarol: Structural insight and human anti-glioblastoma activities. Heliyon 9(7):e17601, 2023. e-Pub 2023. PMID: 37456028.
33. Lai, TH, Ozer, HG, Gasparini, P, Nigita, G, Distefano, R, Yu, L, Ravikrishnan, J, Yilmaz, SA, Gallegos, J, Shukla, SA, Puduvalli, VK, Woyach, JA, Lapalombella, R, Blachly, JS, Byrd, JC, Sampath, D. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. Blood Advances 7(12):2897-2911, 2023. e-Pub 2023. PMID: 36287107.
34. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, Lopez-Janeiro A, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 29(6):1370-1378, 2023. e-Pub 2023. PMID: 37188783.
35. Liang J, Fang D, Gumin J, Najem H, Sooreshjani M, Song R, Sabbagh A, Kong LY, Duffy J, Balyasnikova IV, Pollack SM, Puduvalli VK, Heimberger AB. A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin. Cancers (Basel) 15(4), 2023. e-Pub 2023. PMID: 36831427.
36. Fanucci, K, Pilat, MJ, Shyr, D, Shyr, Y, Boerner, S, Li, J, Durecki, DE, Drappatz, J, Puduvalli, VK, Lieberman, F, Gonzalez, J, Giglio, P, Ivy, SP, Bindra, RS, Omuro, A, LoRusso, P. Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma. Cancer Research Communications 3(2):192-201, 2023. e-Pub 2023. PMID: 36968138.
37. Fanucci, K, Pilat, MJ, Shyr, D, Shyr, Y, Boerner, S, Li, J, Durecki, DE, Drappatz, J, Puduvalli, VK, Lieberman, F, Gonzalez, J, Giglio, P, Ivy, SP, Bindra, RS, Omuro, A, LoRusso, P. Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma. Cancer Research Communications 3(2):192-201, 2023. e-Pub 2023. PMID: 36968138.
38. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv 5(1):vdad032, 2023. e-Pub 2023. PMID: 37114244.
39. Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S. NCCN Guidelines(R) Insights: Central Nervous System Cancers, Version 2.2022. J Natl Compr Canc Netw 21(1):12-20, 2023. e-Pub 2023. PMID: 36634606.
40. Lassman AB, Sepulveda-Sanchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res 28(11):2270-2277, 2022. e-Pub 2022. PMID: 35344029.
41. Xu J, Wu PJ, Lai TH, Sharma P, Canella A, Welker AM, Beattie CE, Elder JB, Easley M, Lonser R, Jacob NK, Pietrzak M, Timmers CM, Lang F, Sampath D, Puduvalli VK. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy. Clin Cancer Res 28(9):1979-1990, 2022. e-Pub 2022. PMID: 35140124.
42. Palmer, JD, Prasad, RN, Fabian, D, Wei, L, Yildiz, VO, Tan, Y, Grecula, JC, Welliver, MX, Williams, TM, Bradley Elder, J, Raval, RR, Blakaj, DM, Haglund, K, Bazan, JG, Kendra, KL, Arnett, AL, Beyer, S, Liebner, DA, Giglio, P, Puduvalli, VK, Chakravarti, A, Wuthrick, EJ. Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases. Radiotherapy and Oncology 170:21-26, 2022. e-Pub 2022. PMID: 35367525.
43. Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol 24(2):229-244, 2022. e-Pub 2022. PMID: 34260721.
44. Griguer, C, Oliva, CR, S Coffey, C, Cudkowicz, ME, Conwit, R, Gudjonsdottir, AL, Ecklund, DJ, Fedler, JK, Neill-Hudson, TM, Nabors, LB, Benge, M, Hackney, JR, Chase, M, Leonard, TP, Patel, TR, Colman, H, de la Fuente, MI, Chaudhary, R, Marder, K, Kreisl, T, Mohile, N, Chheda, MG, Mcneill, K, Kumthekar, P, Dogan, A, Drappatz, J, Puduvalli, VK, Kowalska, A, Graber, JJ, Gerstner, E, Clark, SW, Salacz, ME, Markert, JM. Prospective biomarker study in newly diagnosed glioblastoma. Neuro-Oncology Advances 4(1), 2022. e-Pub 2022. PMID: 35088051.
45. Upadhyay R, Khose S, Pokhylevych H, Paulino AC, McAleer MF, Ghia A, Li J, Yeboa DN, Loghin M, Harrison R, O'Brien B, Kamiya-Matsuoka C, De Groot J, Puduvalli VK, Tatsui C, Alvarez-Breckenridge C, Prabhu S, Rhines L, Zaky W, Lin F, Weinberg JS, Fuller G, Sandberg DI, Johnson JM, McGovern SL. Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis. Neurooncol Adv 4(1):vdac129, 2022. e-Pub 2022. PMID: 36128585.
46. Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM. Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. Eur J Breast Health 17(4):371-377, 2021. e-Pub 2021. PMID: 34651117.
47. Lee, EQ, Selig, W, Meehan, C, Bacha, J, Barone, A, Bloomquist, E, Chang, SM, de Groot, JF, Galanis, E, Hassan, IA, Kalidas, C, Khasraw, M, Kvedar, JC, Lassman, AB, Puduvalli, VK, Sahebjam, S, Schwamm, LH, Tamir, S, Welch, M, Yung, WA, Zadeh, G, Arons, DF, Wen, PY. Report of national brain tumor society roundtable workshop on innovating brain tumor clinical trials. Neuro-oncology 23(8):1252-1260, 2021. e-Pub 2021. PMID: 33822177.
48. Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34215688.
49. Alnahhas, I, Rayi, A, Palmer, JD, Raval, RR, Folefac, E, Ong, SS, Giglio, P, Puduvalli, VK. The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis. Neuro-Oncology Practice 8(1):75-80, 2021. e-Pub 2021. PMID: 33664972.
50. Alnahhas, I, Rayi, A, Prieto, P, Ong, SS, Giglio, P, Puduvalli, VK. Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma. Neuro-Oncology Advances 3(1), 2021. e-Pub 2021. PMID: 34667950.
51. Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv 3(1):vdab141, 2021. e-Pub 2021. PMID: 34693288.
52. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv 3(1):vdab079, 2021. e-Pub 2021. PMID: 34377987.
53. Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, Wong ET, Glas M. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Front Oncol 11:679702, 2021. e-Pub 2021. PMID: 34026655.
54. Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(11):1537-1570, 2020. e-Pub 2020. PMID: 33152694.
55. Alnahhas, I, Rayi, A, Thomas, D, Ong, SS, Giglio, P, Puduvalli, VK. False-positive 1p/19q Testing Results in Gliomas. American Journal of Clinical Oncology: Cancer Clinical Trials 43(11):802-805, 2020. e-Pub 2020. PMID: 32889892.
56. Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol 22(10):1505-1515, 2020. e-Pub 2020. PMID: 32166308.
57. Cheng, X, Geng, F, Pan, M, Wu, X, Zhong, Y, Wang, C, Tian, Z, Cheng, C, Zhang, R, Puduvalli, VK, Horbinski, C, Mo, X, Han, X, Chakravarti, A, Guo, D. Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress. Cell Metabolism 32(2):229-242.e8, 2020. e-Pub 2020. PMID: 32559414.
58. Gatson NTN, Bross SP, Odia Y, Mongelluzzo GJ, Hu Y, Lockard L, Manikowski JJ, Mahadevan A, Kazmi SAJ, Lacroix M, Conger AR, Vadakara J, Nayak L, Chi TL, Mehta MP, Puduvalli VK. Early imaging marker of progressing glioblastoma: a window of opportunity. J Neurooncol 148(3):629-640, 2020. e-Pub 2020. PMID: 32602020.
59. Boutrid, H, Kassem, M, Tozbikian, G, Morgan, E, White, J, Shah, MH, Vandeusen, J, Sardesai, S, Williams, N, Stover, DG, Lustberg, MB, Wesolowski, R, Puduvalli, VK, Williams, TM, Konda, B, Fortier, S, Carbone, DP, Ramaswamy, B, Cherian, M. TTF-1 Positive Primary Small Cell Carcinoma of the Breast. Frontiers in Endocrinology 11, 2020. e-Pub 2020. PMID: 32411090.
60. Freeman, T, Legasto, CS, Schickli, MA, McLaughlin, EM, Giglio, P, Puduvalli, VK, Gonzalez, J. High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neuro-Oncology Advances 2(1), 2020. e-Pub 2020. PMID: 32715297.
61. Alnahhas, I, Lahaye, S, Giglio, P, Mardis, ER, Puduvalli, VK. An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma. Neuro-Oncology Advances 2(1), 2020. e-Pub 2020. PMID: 33880446.
62. Wang JL, Barth RF, Cavaliere R, Puduvalli VK, Giglio P, Lonser RR, Elder JB. Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. PLoS One 15(12):e0244383, 2020. e-Pub 2020. PMID: 33373402.
63. Dornbos D 3rd, Elder JB, Otero JJ, Baiocchi RA, Slone HW, Puduvalli VK, Giglio P. Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation. World Neurosurg 128:381-384, 2019. e-Pub 2019. PMID: 31128312.
64. Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv 3(3):242-255, 2019. e-Pub 2019. PMID: 30692102.
65. Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer 125(3):424-433, 2019. e-Pub 2019. PMID: 30359477.
66. Makary MS, Awan U, Puduvalli VK, Slone HW. Stroke-Like Migraine Attacks after Radiation Therapy Syndrome: Clinical and Imaging Characteristics. J Clin Imaging Sci 9:5, 2019. e-Pub 2019. PMID: 31448156.
67. Nabar GM, Mahajan KD, Calhoun MA, Duong AD, Souva MS, Xu J, Czeisler C, Puduvalli VK, Otero JJ, Wyslouzil BE, Winter JO. Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366, 2018. e-Pub 2018. PMID: 29391794.
68. Goceri E, Goksel B, Elder JB, Puduvalli VK, Otero JJ, Gurcan MN. Quantitative validation of anti-PTBP1 antibody for diagnostic neuropathology use: Image analysis approach. Int J Numer Method Biomed Eng 33(11), 2017. e-Pub 2017. PMID: 28024117.
69. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw 15(11):1331-1345, 2017. e-Pub 2017. PMID: 29118226.
70. Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D, Puduvalli VK. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clin Cancer Res 23(20):6215-6226, 2017. e-Pub 2017. PMID: 28679777.
71. Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK. A novel interaction of PAK4 with PPARgamma to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene 36(37):5309-5320, 2017. e-Pub 2017. PMID: 28534509.
72. Williams MM, Mashaly H, Puduvalli VK, Jin M, Mendel E. Immunoglobulin G4-related disease mimicking an epidural spinal cord tumor: case report. J Neurosurg Spine 26(1):76-80, 2017. e-Pub 2017. PMID: 27517527.
73. Wang JL, Hong CS, Otero J, Puduvalli VK, Elder JB. Genetic Characterization of a Multifocal Ganglioglioma Originating Within the Spinal Cord. World Neurosurg 96:608.e1-608.e4, 2016. e-Pub 2016. PMID: 27671879.
74. Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 129(3):487-494, 2016. e-Pub 2016. PMID: 27406589.
75. Puduvalli VK. Vaccine Therapies Against Gliomas: Prime Time Yet?. Oncology (Williston Park) 30(3):222-3, 2016. e-Pub 2016. PMID: 26984214.
76. Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126(3):527-33, 2016. e-Pub 2016. PMID: 26566652.
77. Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE. Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech 9(2):199-210, 2016. e-Pub 2016. PMID: 26659251.
78. Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol 126(1):185-192, 2016. e-Pub 2016. PMID: 26476729.
79. Walbert T, Glantz M, Schultz L, Puduvalli VK. Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey. J Neurooncol 126(2):337-45, 2016. e-Pub 2016. PMID: 26518539.
80. Usubalieva A, Pierson CR, Kavran CA, Huntoon K, Kryvenko ON, Mayer TG, Zhao W, Rock J, Ammirati M, Puduvalli VK, Lehman NL. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib. J Neuropathol Exp Neurol 74(10):960-9, 2015. e-Pub 2015. PMID: 26352988.
81. Fauzi MFA, Gokozan HN, Elder B, Puduvalli VK, Pierson CR, Otero JJ, Gurcan MN. A multi-resolution textural approach to diagnostic neuropathology reporting. J Neurooncol 124(3):393-402, 2015. e-Pub 2015. PMID: 26255070.
82. Walbert T, Puduvalli VK, Taphoorn MJB, Taylor AR, Jalali R. International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neurooncol Pract 2(2):62-69, 2015. e-Pub 2015. PMID: 31386064.
83. Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?. J Neurooncol 123(1):141-50, 2015. e-Pub 2015. PMID: 25894594.
84. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17(2):266-73, 2015. e-Pub 2015. PMID: 25239666.
85. Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci 353(1-2):92-7, 2015. e-Pub 2015. PMID: 25934342.
86. Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther 22(9):1678-87, 2014. e-Pub 2014. PMID: 24895995.
87. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135-40, 2014. e-Pub 2014. PMID: 24803001.
88. Theeler BJ, Ellezam B, Sadighi ZS, Mehta V, Tran MD, Adesina AM, Bruner JM, Puduvalli VK. Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro Oncol 16(6):841-7, 2014. e-Pub 2014. PMID: 24470550.
89. Anderson MD, Hamza MA, Hess KR, Puduvalli VK. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 16(6):823-8, 2014. e-Pub 2014. PMID: 24596117.
90. Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VK. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene 32(26):3119-29, 2013. e-Pub 2013. PMID: 22945648.
91. Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, Tucker SL, Crawford CN, Khan M, Khatua S, Gilbert MR, Brown PD, Mahajan A. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 86(2):277-84, 2013. e-Pub 2013. PMID: 23433794.
92. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 18(21):6032-9, 2012. e-Pub 2012. PMID: 22923449.
93. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 2012. e-Pub 2012. PMID: 22086614.
94. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108(3):491-8, 2012. e-Pub 2012. PMID: 22426926.
95. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119(5):1162-72, 2012. e-Pub 2012. PMID: 22096249.
96. Xu J, Sampath D, Lang FF, Prabhu S, Rao G, Fuller GN, Liu Y, Puduvalli VK. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 105(2):241-51, 2011. e-Pub 2011. PMID: 21598070.
97. Wu J, Langford LA, Schellingerhout D, Guha-Thakurta N, Tummala S, Weinberg JS, Puduvalli VK. Progressive multifocal leukoencephalopathy in a patient with glioblastoma. J Neurooncol 103(3):791-6, 2011. e-Pub 2011. PMID: 21120583.
98. Ong SS, Bruner J, Schellingerhout D, Puduvalli VK. Papillary endothelial hyperplasia presenting as recurrent malignant glioma. J Neurooncol 102(3):491-8, 2011. e-Pub 2011. PMID: 20740304.
99. Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102(2):273-80, 2011. e-Pub 2011. PMID: 20652724.
100. Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis 2(2):e121, 2011. e-Pub 2011. PMID: 21368892.
101. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168-74, 2010. e-Pub 2010. PMID: 20124186.
102. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94(2):229-34, 2009. e-Pub 2009. PMID: 19267183.
103. Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-20, 2009. e-Pub 2009. PMID: 19672263.
104. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113(16):3744-53, 2009. e-Pub 2009. PMID: 19096009.
105. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 2008. e-Pub 2008. PMID: 18581057.
106. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-22, 2008. e-Pub 2008. PMID: 18314417.
107. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-15, 2008. e-Pub 2008. PMID: 18316473.
108. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3):271-7, 2007. e-Pub 2007. PMID: 17031561.
109. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80(1):83-90, 2006. e-Pub 2006. PMID: 16639492.
110. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899-907, 2006. e-Pub 2006. PMID: 16914578.
111. Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78(1):85-90, 2006. e-Pub 2006. PMID: 16391896.
112. Puduvalli VK, Li JT, Chen L, McCutcheon IE. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 65(4):1547-53, 2005. e-Pub 2005. PMID: 15735044.
113. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10(1):233-43, 2005. e-Pub 2005. PMID: 15711939.
114. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21):4282-9, 2004. e-Pub 2004. PMID: 15514370.
115. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4):308-14, 2004. e-Pub 2004. PMID: 15184994.
116. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer 98(2):363-8, 2003. e-Pub 2003. PMID: 12872358.
117. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65(3):259-66, 2003. e-Pub 2003. PMID: 14657600.
118. Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20(22):4440-7, 2002. e-Pub 2002. PMID: 12431966.
119. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol 4(4):268-77, 2002. e-Pub 2002. PMID: 12356357.
120. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20(5):1383-8, 2002. e-Pub 2002. PMID: 11870183.
121. Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17(5):963-9, 2000. e-Pub 2000. PMID: 11029499.
122. Saitoh Y, Goto T, Puduvalli VK, Murakami M, Kochi M, Levin VA, Kyritsis AP, Ushio Y. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells. Int J Oncol 15(3):499-504, 1999. e-Pub 1999. PMID: 10427131.
123. Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 5(8):2230-5, 1999. e-Pub 1999. PMID: 10473110.
124. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 1998. e-Pub 1998. PMID: 9472109.
125. Puduvalli VK, Sella A, Austin SG, Forman AD. Carpal tunnel syndrome associated with interleukin-2 therapy. Cancer 77(6):1189-92, 1996. e-Pub 1996. PMID: 8635142.

Review Articles

1. Gomez-Manzano C, Shin DH, Alvarez-Breckenridge C, Gillard AG, Morad G, Puduvalli VK, Alonso MM, Lang FF, Fueyo J. Diverse origin and nature of tumor-infiltrating lymphocytes: the infection hypothesis. J Immunother Cancer 14(7), 2026. e-Pub 2026. PMID: 42463282.
2. Jones G, Anderson JL, Nguyen PTT, Gleber-Netto FO, Hwang WL, Puduvalli VK, Monje M, Amit M. Novel approaches to clinical trial design in cancer neuroscience. Neuron 113(17):2791-2813, 2025. e-Pub 2025. PMID: 40907474.
3. Dasgupta P, Puduvalli VK. Diversity of metabolic features and relevance to clinical subtypes of gliomas. Semin Cancer Biol 112:126-134, 2025. e-Pub 2025. PMID: 40194749.
4. Rock V, Ahluwalia MS, Anthony M, Arons D, Arzbaecher J, Dunbar E, Fraher C, Freund M, Gondi V, Khanuja S, Leach D, Loughan AR, Musella A, Oliver K, Paabo K, Puduvalli VK, Shaffer GD, Thomas AA, Wallgren K, Wefel JS, Yu JS, Zada G, Willmarth N, DeVitto R. Guiding principles for adult CNS tumor treatment programs. Neurooncol Adv 7(1):vdaf169, 2025. e-Pub 2025. PMID: 40980442.
5. Kotecha, R, Schiff, D, Chakravarti, A, Fleming, JL, Brown, P, Puduvalli, VK, Vogelbaum, MA, Gondi, V, Gallus, M, Okada, H, Mehta, MP. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. Journal of Clinical Oncology 42(21):2588-2598, 2024. e-Pub 2024. PMID: 38833641.
6. Kotecha, R, Schiff, D, Chakravarti, A, Fleming, JL, Brown, P, Puduvalli, VK, Vogelbaum, MA, Gondi, V, Gallus, M, Okada, H, Mehta, MP. Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era. Journal of Clinical Oncology 42(21):2588-2598, 2024. e-Pub 2024. PMID: 38833641.
7. Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: Current and emerging concepts. Neurooncol Adv 5(1):vdad009, 2023. e-Pub 2023. PMID: 36968288.
8. Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res 28(4):585-593, 2022. e-Pub 2022. PMID: 34561270.
9. Rayi A, Alnahhas I, Ong S, Giglio P, Puduvalli VK. Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol 22(11):105, 2021. e-Pub 2021. PMID: 34613491.
10. Alnahhas, I, Alsawas, M, Rayi, A, Palmer, JD, Raval, RR, Ong, SS, Giglio, P, Murad, MH, Puduvalli, VK. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma. Neuro-Oncology Advances 2(1), 2020. e-Pub 2020. PMID: 33150334.
11. Carpenter CD, Alnahhas I, Gonzalez J, Giglio P, Puduvalli VK. Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Rev Neurother 19(7):663-677, 2019. e-Pub 2019. PMID: 31106606.
12. Puduvalli VK, Hoang N. Chemotherapy of High-Grade Astrocytomas in Adults. Prog Neurol Surg 31:116-144, 2018. e-Pub 2018. PMID: 29393181.
13. Puduvalli VK, Chaudhary R, McClugage SG, Markert J. Beyond Alkylating Agents for Gliomas: Quo Vadimus?. Am Soc Clin Oncol Educ Book 37:175-186, 2017. e-Pub 2017. PMID: 28561663.
14. Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 117:307-36, 2004. e-Pub 2004. PMID: 15015567.
15. Puduvalli VK. Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 3(6):467-75, 2001. e-Pub 2001. PMID: 11595114.
16. Puduvalli VK, Sawaya R. Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50(1-2):189-200, 2000. e-Pub 2000. PMID: 11245279.
17. Puduvalli VK, Yung AW. New frontiers in therapy of malignant gliomas. Forum (Genova) 8(3):261-9, 1998. e-Pub 1998. PMID: 9755291.

Other Articles

1. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, Lopez-Janeiro A, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med 31(9):3204, 2025. PMID: 40691367.
2. Alnahhas, I, Alsawas, M, Rayi, A, Palmer, JD, Raval, RR, Ong, SS, Giglio, P, Murad, MH, Puduvalli, VK Erratum. Neuro-Oncology Advances 3(1), 2021. PMID: 34258581.
3. Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech 9(9):1063-5, 2016. PMID: 27604693.

Editorials

1. Puduvalli VK. Demystifying demethylator sensitivity in gliomas: role for TERT and DNMT1. Neuro Oncol 23(1):7-8, 2021. PMID: 33264399.
2. Balogun, J, Haynes, C, Lwin, Z, Nduom, E, Puduvalli, VK, Venere, M, Zadeh, G. SNO 25th anniversary history series. Neuro-oncology 22(11):1551-1552, 2020. PMID: 32995879.
3. Venere, M, Zadeh, G, Puduvalli, VK, Haynes, C. SNO 25th anniversary history series. Neuro-oncology 22(9):1231-1232, 2020. PMID: 32991721.
4. Puduvalli, VK, Venere, M, Haynes, C, Zadeh, G. SNO 25th anniversary history series. Neuro-oncology 22(8):1053-1055, 2020. PMID: 32804242.
5. Venere, M, Zadeh, G, Puduvalli, VK, Haynes, C. SNO 25 anniversary history series. Neuro-oncology 22(6):739-740, 2020. PMID: 32518956.
6. Venere, M, Zadeh, G, Puduvalli, VK, Haynes, C. Celebrating SNO's official journal, Neuro-Oncology. Neuro-oncology 22(5):585-586, 2020. PMID: 32415306.
7. Venere, M, Zadeh, G, Puduvalli, VK, Haynes, C. The Society for Neuro-Oncology. Neuro-oncology 22(4):435-436, 2020. PMID: 32095809.

Abstracts

1. Puduvalli VK, Tim Gregory, Jiyong Liang. Central Nervous System Tumors. ASCO Annual Meeting, 2023. e-Pub 2023.
2. Barney C, Brown A, Lowe M, McAleer M, Grosshans D, deGroot J, Puduvalli V, Gilbert M, Vats T, Brown P, Mahajan A. Proton Craniospinal Irradiation For Adults With Medulloblastoma. Neuro-Oncology: Abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15-18, 2012, Washington, D. C 14(suppl 6):vii135, 2012. e-Pub 2012.
3. Theeler B, Ellezam B, Melguizo-Gavilanes I, Shonka N, Bruner J, Puduvalli V. Actionable Mutations in Posterior Fossa Diffuse Gliomas in Adults: Clinicopathologic Correlation. Neuro-Oncology: Abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15-18, 2012, Washington, D. C 14(suppl 6):vi79, 2012. e-Pub 2012.
4. Yust-Katz S, Liu V, Sanghee K, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung A, Gilbert M. Phase I/Ib Study Of Lonafarnib And Temozolomide In Patients With Recurrent Or Temozolomide Refractory Glioblastoma. Neuro-Oncology: Abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15-18, 2012, Washington, D. C 14(suppl 6):vi68, 2012. e-Pub 2012.
5. Hamza M, Puduvalli V. Outcome Of Patients With Malignant Glioma And Non-Neuronal Primary Neoplasms. Neuro-Oncology: Abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15-18, 2012, Washington, D. C 14(suppl6):vi82, 2012. e-Pub 2012.
6. Ellezam B, Theeler B, Sadighi Z, Mehta V, Tran M, Adesina A, Puduvalli V, Bruner J. Adult Pilocytic Astrocytoma: Clinical Features And Molecular Analysis. Neuro-Oncology: Abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology, November 15-18, 2012, Washington, D. C 14(suppl 6):vi111, 2012. e-Pub 2012.
7. Dziurzynski K, Blas-Boria D, Suki D, Cahill D, Prabhu S, Puduvalli V, Levine N. Retrospective analysis of outcomes after surgical biopsy or debulking in patients with butterfly glioblastomas. Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii161, 2011. e-Pub 2011.
8. Mahajan A, Vats T, Grosshans D, McAleer MF, Brown PD, Chintagumpala M, Vats T, Puduvalli V, Yock T. A Matched Comparison of Blood Counts During Whole Versus Partial Vertebral Proton Craniospinal Irradiation. Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii128, 2011. e-Pub 2011.
9. Puduvalli VK, Penas Prado M, Hess KR, Hunter K, Ictech S, Groves MD, Gilbert MR, Liu V, Conrad CA, de Groot JF, Loghin ME, Colman H, Levin VA, Yung WKA. Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults with Recurrent Glioblastoma Multiforme - Results of the phase I arm. Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii49, 2011. e-Pub 2011.
10. Sadighi ZS, Khatua S, Langford LA, Puduvalli VK. Response to Bevacizumab: A Role for Anti-angiogenic Therapy in Recurrent Pilocytic Astrocytoma in Adults?. Neuro-Oncology In: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii47, 2011. e-Pub 2011.
11. Hamilton JD, Wang J, Levin VA, Hou P, Loghin ME, Gilbert MR, Leeds NE, deGroot JF, Puduvalli VK, Jackson EF, Yung WKA, Kumar AJ. Normalized baseline ADC values predict problems associated with Bevacizumab treatment for glioblastoma multiforme or brain radiation induced necrosis. Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii136-137, 2011. e-Pub 2011.
12. Lassman AB, Wang M, Gilbert MR, Aldape KD, Beumer JJ, Wright J, Takebe N, Puduvalli VK Hormigo A, Gaur R, Werner-Wasik M, Mehta MP. Phase II trial of dasatinib in target selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii64, 2011. e-Pub 2011.
13. Theeler BJ, Melguizo-Gavilanes I, Shonka NA, Qiao W, Wang X, Mahajan A, Puduvalli V. Natural history and characteristics of brainstem and cerebellar gliomas in adults. Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii63, 2011. e-Pub 2011.
14. Colman H, Gilbert MR, Yung WKA, Aldape K, De Groot J, Conrad C, Levin V, Groves M, Loghin ME, Pelloski C, Puduvalli V. A Phase I Study of Sorafenib with Radiation and Temozolomide in Newly Diagnosed Glioblastoma. Neuro-Oncology: Abstracts from the 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA 13(suppl 3):iii61, 2011. e-Pub 2011.
15. Melguizo I, Hess KR, Blas-Boria D, Bruner J, Guha-Thakurta N, Puduvalli VK. The effect of surgery in determining pseudoprogression and predicting outcome in adults with glioblastoma. J Clin Oncol. In: Proceedings of the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL 29(15S):156s, 2011. e-Pub 2011.
16. Wen PY, Puduvalli VK, Kuhn JG, Reid JM, Lamborn K, Cloughesy TF, Chang SM, Drappatz J, Yung WKA, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Desideri S, Ye X, Ames MM, Espinoza-Delgado IJ, Grossman SA, Prados M. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J Clin Oncol. In: Proceedings of the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, 2011, Chicago, IL 29(15S):148s, 2011. e-Pub 2011.
17. Wu J, Shen R, Puduvalli V, Koul D, Yung WKA. Cellular Activity of Novel HSP90 Inhibitor NVP-HSP 990 for Treatment of Human Glioblastoma. Neuro-Oncology. In: Proceedings of the 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010 12(11 suppl iv):iv91, 2010. e-Pub 2010.
18. Walbert T, Puduvalli V. Primary Spinal Cord Glioblastoma: Response to Therapy with Bevacizumab. Neuro-Oncology. In: Proceedings of the 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010 12(11 suppl iv):iv44, 2010. e-Pub 2010.
19. Puduvalli VK, Penas-Prado M, Gilbert MR, Groves MD, Hess KR, Levin VA, deGroot JF, Colman H, Conrad CA, Loghin ME, Hunter K, Yung WKA. Phase 1 study of Vorinostat combined with Isotretinoin and Carboplatin in Adults with Recurrent Malignant Gliomas. Neuro-Oncology. In: Proceedings of the 15th Annual Meeting of the Society for Neuro-Oncology, November 18-21, 2010 12(11 suppl iv):iv69, 2010. e-Pub 2010.
20. Melguizo I, Bruner J, Guha-Thakurta K, Hess R, Puduvalli VK. Characterization of pseudo progression in patients with glioblastoma: Is histology the gold standard?. J Clin Oncol. In: Proceedings of the 2010 Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL 28(15S):199s, 2010. e-Pub 2010.
21. Wu J, Gilbert MR, Degroot JF, Yung WA, Puduvalli VK. Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab. J Clin Oncol. In: Proceedings of the 2010 Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL 28(15s):185s, 2010. e-Pub 2010.
22. Walbert T, Gilbert MR, Groves MD, Puduvalli V, Yung WA, Conrad CA, Bobustuc GC, Colman HK, Bekele BN, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or Lomustine for recurrent high-grade glioma. J Clin Oncol. In: Proceedings of the 2010 Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL 28(15s):194s, 2010. e-Pub 2010.
23. Ong S, Wei Q, Bekele N, Guha-Thakurta G, Puduvalli V. Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas. J Clin Oncol. In: Proceedings of the 2010 Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL 28(15s):184s, 2010. e-Pub 2010.
24. Puduvalli V. Enhancing TRAIL induced apoptosis by XIAP”. In: Proceedings of the Agents Pathway poster discussion session entitled “Identification and Credentialing of Novel Agents and combinations”. 2009 NCI Translational Science Meeting. Washington, DC, Nov 5 - Nov 7, 2009, 2009. e-Pub 2009.
25. Van den Bent M, Liepa AM, Puduvalli VK, Carpenter, A, Cher L, Mason W, Hong S, Wick W. Measuring health status in recurrent glioblastoma: Validation of the EuroQol EQ-5D. Neuro-Oncology. In: Proceedings of the 2009 Joint Meeting of the Society of Neuro-Oncology (SNO) and AANS/CNS Section on tumors 11(5):655, 2009. e-Pub 2009.
26. Prados M, Gilbert M Kuhn J, Lamborn K, Cloughesy T, Lieberman F, Puduvalli V, Robins HL Lassman A Wen PY. Phase I/II study of sorafenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncology, Proceedings of the Annual 2009 American Society of Clinical Oncology (ASCO) meeting, May 29 - June 2, 2009, Orlando FL 27(15s):88s, 2009. e-Pub 2009.
27. Kuhn JG, Gilbert M, Wen P, Cloughesy T, Cooper J, Puduvalli V, Deangelis L, Lieberman F, Lamborn K, Prados M. Interaction between sorafenib and erlotinib. J Clin Oncology. Proceedings of the Annual 2009 Annual meeting of American Society of Clinical Oncology (ASCO), May 29 - June 2, 2009, Orlando FL 27(15s):108s, 2009. e-Pub 2009.
28. Gopisetty G, Xu J, Colman H, Puduvalli VK. Transcription factors SP 1 and c-myc are involved in the regulation of CD133 in glioma stem-like cells. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research (AACR) 2009, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
29. Puduvalli VK, Wick W, Chamberlain M, Carpenter A, Cher L, Mason W, Van Den Bent M, Hong S, Thornton DE, Fine H. Enzastaurin versus lomustine in the treatment of recurrent, intracranial glioblastoma: A phase III study. Neuro-Oncology. In: Proceedings of the 13th Annual Meeting of the Society for Neuro-Oncology, November 20 -22, 2008 10(5):435, 2008. e-Pub 2008.
30. Galanis E, Jaeckle K, Buckner J, Maurer M, Hardwick J, Puduvalli V, Lamborn K, Luhn J Prados M, Wen PY. Vorinostat in glioblastoma multiforme (GBM): Updated results from Phase I and II trials provide the rationale for further clinical development. In: Proceedings of the 1st International Conference of the European Society for Medical Oncology, 2008. e-Pub 2008.
31. Puduvalli VK, Xu J, Liu Y, Lang FF, Prabhu S, Rao G. Human glioblastoma organotypic slice culture: A novel model for the study of tumor biology and therapeutic response. Proceedings of the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, October 20 - 24, 2008, 2008. e-Pub 2008.
32. Groves M, Hess KR, Puduvalli V, Colman H, Conrad C, Loghin M, DeGroot J, Gilbert M, Weinberg J, Yung WKA, Liu TJ. Cerebrospinal fluid vascular endothelial growth factor and stromal cell derived factor-1 levels in patients with neoplastic meningitis due to breast cancer, lung cancer, and melanoma: Are disease biomarkers ready for clinical use?. Neuro-Oncology. In Proceedings of the 13th Annual Meeting of the Society for Neuro-Oncology, November 20 -22, 2008 10(5):440, 2008. e-Pub 2008.
33. Gopisetty G, Sampath D, Xu J, Colman H, Puduvalli VK. Epigenetic regulation of CD1333 by promoter methylation in glioma stem cells. Neuro-Oncology. In: Proceedings of the 13th Annual Meeting of the Society for Neuro-Oncology, November 20 -22, 2008 10(5):517, 2008. e-Pub 2008.
34. Puduvalli VK, Lang FF, Liu Y. Inhibition of XIAP facilitates trail-induced apoptosis and improves survival in a bioluminescent glioma xenograft model. Neuro-Oncology. In: Proceedings of the 13th Annual Meeting of the Society for Neuro-Oncology, November 20 -22, 2008 10(5):398, 2008. e-Pub 2008.
35. Fine HA, Puduvalli VK, Chamberlain MC, Carpentier AF, Cher L, Mason WP, van den Bent MJ, Hong S, Thornton D, Wick W. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study. J Clin Oncol. In Proceedings of the American Society of Clinical Oncology, May 30 - June 2, 2008 26(May 20 suppl), 2008. e-Pub 2008.
36. van den Bent MJ, Wick W, Liepa AM, Puduvalli VK, Carpentier AF, Cher L, Mason WP, Taphoorn MJ, Hong S, Fine HA. Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU). J Clin Oncol. In Proceedings of the American Society of Clinical Oncology, May 30 - June 2, 2008 26(May 20 suppl), 2008. e-Pub 2008.
37. Puduvalli VK, Liu Y, Lang F, Albarraccin C, Fuller G. Ad-s TRAIL, an adenoviral construct expressing soluble TRAIL, improves survival in a bioluminescence imageable intracranial xenograft model of malignant glioma. In: Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, April 12 – 16, 2008. e-Pub 2008.
38. Sampath D, Calin GA, Puduvalli VK, Taccioli C, Ewald BJ, Keating MJ, Plunkett W. MicroRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic response in chronic lymphocytic leukemia. In: Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, April 12 – 16, 2008, 2008. e-Pub 2008.
39. Wen P, Puduvalli V, Kuhn J, Reid J, Cloughesy T, Yung WKA, Drappatz J, Lamborn K, Gilbert M, Butowski N, Levin V, Chang S, Kesari S, Robbins HI, McGovern R, Richon V, Frankel S, Ames M, Zweibel J, Prados M. Phase I study of Vorinostat (Suberoylanilide Hydroxamic Acid (SAHA) in combination with Temozolomide in patients with malignant gliomas (NABTC 04-05). Neuro-Oncology. Proceedings of the 12th Annual Meeting of the Society for Neuro-Oncology, (SNO) Dallas TX, November 15-18, 2007 9(4):518, 2007. e-Pub 2007.
40. Conrad C, Maher E, Cloughesy T, Fink K, Priebe W, Madden T, Meyer C, Foster P, Groves M, Gilbert M, Levin V, Puduvalli V, Colman H, Yung WKA. Results of a phase I trial with the novel anthracycline derivative RTA-744 in patients with recurrent primary brain tumors. Neuro-Oncology. . Proceedings of the 12th Annual Meeting of the Society for Neuro-Oncology, (SNO) Dallas TX, November 15-18, 2007 9(4):523, 2007. e-Pub 2007.
41. Gilbert M, Gaupp P, Ictech S, Hess K, Groves M, Levin V, Conrad C, Puduvalli V, Colman H, deGroot J, Hsu S, De Porre P, Yung WKA. A phase I/II study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, Zar) in recurrent glioblastoma (GBM). Neuro-Oncology. Proceedings of the 12th Annual Meeting of the Society for Neuro-Oncology, (SNO) Dallas TX, November 15-18, 2007 9(4):524, 2007. e-Pub 2007.
42. Grewal J, Kallio M, Tummala S, Puduvalli V. Coincidence or association: Two 19Q disorders in the same patient: 1P/19Q co-deleted oligodendroglioma and myotonic dystrophy type 1. Neuro-Oncology. Proceedings of the 12th Annual Meeting of the Society for Neuro-Oncology, (SNO) Dallas TX, November 15-18, 2007 9(4):546, 2007. e-Pub 2007.
43. Penas-Prado M, Puduvalli V, Groves M, Conrad C, Gilbert M, Levin VA, Yung WKA. Temozolomide plus 13-Cis-Retinoic Acid (TMZ/CRA) as first line chemotherapy for newly diagnosed glioblastoma multiforme (GBM): A retrospective study. Neuro-Oncology. Proceedings of the 12th Annual Meeting of the Society for Neuro-Oncology, (SNO) Dallas TX, November 15-18, 2007 9(4):523, 2007. e-Pub 2007.
44. Wen PY, Puduvalli V, Kuhn J Reid J, Cloughesy T, Yung WA, Chang SM, Robbins HI, McGovern R Ames M Prados MD. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas. J of Clinical Oncology, Proceedings from Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois, June 1-5, 2007 25(18S):2039, 2007. e-Pub 2007.
45. Sampath D, Puduvalli VK, Atadja P, Keating M, Plunkett W. Histone deacetylase inhibitors activate p73 to target chronic lymphocytic leukemia. Proceedings from American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, CA, April 14 – 18, 2007, 2007. e-Pub 2007.
46. Puduvalli VK, Xu J, Sampath D, Prabhu S, Lang FF, Liu Y. p21 Waf1 is unregulated in ex-vivo human glioma slice cultures and delays vorinostat-induced cell cycle arrest and apoptosis in vitro. Proceedings from American Association for Cancer Research (AACR) Annual Meeting, Los Angeles, CA, April 14 – 18, 2007, 2007. e-Pub 2007.
47. Penas-Prado M, Puduvalli VK. Medulloblastoma in adults: A retrospective review of the M. D. Anderson Cancer Center (MDACC) experience. Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):448, 2006. e-Pub 2006.
48. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson E, Levin VA, Conrad CA, Hsu S, Colman H, Ritterhouse M, Ichtech S, Yung WKA. Phase II trial of Irinotecan and Thalidomide in adult patients with recurrent glioblastoma multiforme. Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):450, 2006. e-Pub 2006.
49. Gilbert MR, Gonzalez J, Hunter K, Hess K, Chang E, Puduvalli VK, Groves M, Colman H, Conrad C, Levin V, Woo S, Mahajan A, Hsu S, de Groot J, Yung WKA. A Phase I study for a factorial design of dose-dense Temozolomide (TMZ) alone and in Combination with permutations of Thalidomide (THAL), Isotretinoin (CRA) and/or Celecoxib (CEL) as post-chemoradiation adjuvant therapy for newly diagnosed glioblastoma (GBM). Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):442, 2006. e-Pub 2006.
50. Puduvalli VK, Xu J, Sampath D, Liu Y. Vorinostat (Suberoylanilide Hydroxamic Acid) induces G2-M arrest and apoptosis in glioma cells. Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):416, 2006. e-Pub 2006.
51. Gilbert MR, Gaupp P, Liu V, Conrad C, Colman H, Groves M, Puduvalli V, Levin V, Hsu S, Horowitz J, Yung W. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Ionafarnib (Sarazar, SCH66336) in recurrent glioblastoma. J of Clinical Oncology, Proceedings from 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006 24(18S):1556, 2006. e-Pub 2006.
52. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung, WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. J of Clinical Oncology, Proceedings from . 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006 24(18S):1564, 2006. e-Pub 2006.
53. Wong FC, Groves M, Papadopulos N, Conrad C, Meyers C, Fonnegra A, Puduvalli V, Hsu S, Kim EE. A phase I study using I-131 Nal to treat leptomeningeal metastasis via lumbar puncture. J Nuc Med 47(Supp 1):80P, 2006. e-Pub 2006.
54. Krishnan S, Shentu S, Schwartz DL, Puduvalli VK. Suberoylanilide hydroxamic acid (SAHA) sensitizes pancreatic cancer cells to radiation therapy. Proceedings from poster presentation at the 52nd Annual Meeting of the Radiation Research Society, Denver CO, Oct 17, 2005, 2005. e-Pub 2005.
55. Puduvalli VK, Giglio P, Groves MD, Hess K, Jackson E, Mahankali S, Gilbert MR, Levin VA, Conrad CA, Hsu S, Colman H, Subramaniam H, Hunter G, Yung WKA. Phase II trial of Thalidomide in combination with Irinotecan in adults with recurrent glioblastomas. J of Clinical Oncology, Proceedings from 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 13-17, 2005 23(16S):1524, 2005. e-Pub 2005.
56. Groves MD, Puduvalli V, Gilbert MR, Conrad CA, Hsu S, Colman H, Hess K, Levin VA, Yung, WKA. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. J of Clinical Oncology, Proceedings from 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 13-17, 2005 23(16S):1519, 2005. e-Pub 2005.
57. Groves MG, Puduvalli V, Gilbert, M, Conrad CA, Liu V, Hess K, Yung WKA, Levin VA. Matrix metalloproteinase inhibitor-induced joint-related toxicity predicts prolonged progression-free survival in recurrent high-grade glioma trials. Proceedings of the Society of Neuro-Oncology/6th Annual Meeting of the European Association of Neuro-Oncology/2nd Quadrennial Meeting of the World Federation of Neuro-Oncology, 2005. e-Pub 2005.
58. Puduvalli VK, Xu J, Sampath, D. Suberoylanilide hydroxamic acid (SAHA) induces G2 arrest and apoptosis in gliomas. Proceedings of the 96th Annual meeting of the American Association for Cancer Research (AACR) 46:1808, 2005. e-Pub 2005.
59. Wen PY, Yung WKA, Lamborn K, Peng, B, Dahia P, Abrey, L, Raiser J, Cloughesy T, Fink K, Gilbert M, Chang, S, Junck L, Schiff D, Lieberman F, Fine H, Mehra M, Robins JI, DeAngelis LM, Hess, Groves M, Puduvalli VK, Levin V, Conrad C, Kuhn J, Maher E, Hayes M, Silberman S, Letvak L, Capdeville R, Kaplan R, Murgo A, Stiles C, Prados MD. Phase I/II study of Imatinib Mesylate (ST1571) for patients with recurrent malignant gliomas (NABTC 98-08). Neuro-Oncology, Proceedings from 9th Annual Meeting of the Society for Neuro-Oncology 6(4):385, 2004. e-Pub 2004.
60. Groves MD, Liu TJ, Hess KR, Forman AD, Hsu SH, Gilbert MR, Colman H, Puduvalli VK, Conrad CA, Yung, WKA. Cerebrospinal fluid VEGF levels as a biomarker of neoplastic meningitis. Neuro-Oncology, Proceedings from 9th Annual Meeting of the Society for Neuro-Oncology 6(4):352, 2004. e-Pub 2004.
61. Gilbert MR, Hess K, Gaupp P, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, DePorre P, Yung WKA. A Phase I study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, R115777) in recurrent glioblastoma: A dose and schedule intensive regimen. Neuro-Oncology, Proceedings from 9th Annual Meeting of the Society for Neuro-Oncology 6(4):375, 2004. e-Pub 2004.
62. Puduvalli VK, Xu J, Liu X, Sampath D. In vitro activity of SAHA, an HDAC inhibitor, against gliomas. Proceedings of the American Association for Cancer Research (AACR) Special Conference on Chromatin, Chromosomes, and Cancer Epigenetics, Waikoloa Hawaii, November 10 – November 14, 2004, 2004. e-Pub 2004.
63. Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas (MG) not on EIAEDs. Journal of Clinical Oncology, Proceedings from 2004 ASCO Annual Meeting, New Orleans, LA, June 6, 2004 22 (14S):#1502, 2004. e-Pub 2004.
64. Groves MD, Baumgartner KE, Conrad CA, Chamberlain M, Hsu S, Glantz M, Gilbert M, Forman A, Puduvalli V, Colman H, Yung WKA. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neurology, Proceedings from the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, April 24 - May 1, 2004 62 (Suppl 5):A475, 2004. e-Pub 2004.
65. Puduvalli VK, Sampath D, Liu Y. In vitro activity of the HDAC inhibitor Suberoylanilide hydroxamic acid (SAHA) against gliomas. Proceedings from the 95th Annual Meeting of the American Association for Cancer Research (AACR), abstract #4171, Orlando, Florida, March 27-31, 2004, 2004. e-Pub 2004.
66. Puduvalli VK, Sampath D, Liu Y. In vitro activity of the HDAC inhibitor Suberoylanilide hydroxamic acid (SAHA) against gliomas. Proceedings from 95th Annual Meeting of the American Association for Cancer Research (AACR):Abstract #4171, 2004. e-Pub 2004.
67. Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Puduvalli V, Levin VA, Yung WKA, Wei Q. Polymorphism of DNA double-strand break repair gene XRCC7 and risk of glioma. Neuro-Oncology - Proceedings from Annual Meeting of the Society for Neuro-Oncology, Keystone, CO, 5(4):315, 2003. e-Pub 2003.
68. Groves M, Conrad C, Chamberlain M, Hsu S, Gilbert M, Forman A, Levin V, Puduvalli V, Colman H, Yung WKA. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology, Proceedings 8th Annual Meeting of the Society for Neuro-Oncology, Keystone, CO, 5(4):350, 2003. e-Pub 2003.
69. Gilbert MR, Hess K, Liu V, Groves M, Puduvalli V, Conrad C, Levin V, Yung WKA. Combination therapy using radiation and cytostatic agents: A cautionary tale. Neuro-Oncology, Proceedings from 8th Annual Meeting of the Society for Neuro-Oncology, Keystone, CO, 5(4):343, 2003. e-Pub 2003.
70. Puduvalli, V, Yung WKA, Prados M, Kuhn J, Hess K, Groves, M, Levin V, Chang S, Zwiebel J, Cloughesy T. Phase II trial of fenretinide in patients with recurrent malignant gliomas – A North American Brain Tumor Consortium study. Meeting Proceedings of the American Society of Clinical Oncology, 39th Annual Meeting, Chicago, IL 22:#419, 2003. e-Pub 2003.
71. Tremont-Lukats IW, Puduvalli V. Diagnostic performance of 201 thallium single photon emission computed tomography (201T spect) and MRS in patients with previously irradiated gliomas with new enhancing lesions on MRI. Neuro-Oncology, Proceedings from Society for Neuro-Oncology Seventh Annual Meeting, San Diego CA, 4(4):363, 2002. e-Pub 2002.
72. Tremont-Lukats IW, Puduvalli V, Groves MD. Can Spect, MRS, and dynamic MRI help clinicians to distinguish tumor recurrence from treatment effect: A comparison using post-test probabilities. Neuro-Oncology, Proceedings from the Fifth Congress of the European Association for Neuro-Oncology, Florence Italy 4, Supplement 1:Abstract #316, 2002. e-Pub 2002.
73. Levin VA, Phuphanich S, Glantz MJ, Mason WP, Groves MD, Recht LD, Shaffrey M, Puduvalli V, Roeck B, Zhang MH, Collier MA. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proceedings from American Society of Clinical Oncology Annual meeting, 2002. e-Pub 2002.
74. Puduvalli V, Ridgway L, XU R, Nangia J, Bruner JM, Kyritsis AP. Modulation of apoptotic and survival pathways in gliomas by TRAIL. Proceedings of the American Association for Cancer Research 43:Abstract #3488, 2002. e-Pub 2002.
75. Puduvalli V, McCutcheon IE, Chen L, Li JT. Induction of apoptosis in primary meningioma cells by fenretinide. Proceedings of the American Association for Cancer Research 43:Abstract #4685, 2002. e-Pub 2002.
76. Puduvalli VK. Poster Presentation “Identification of a novel protein that associates with DR5– the receptor for TRAIL”. Proceedings from the American Academy for Cancer, 2001. e-Pub 2001.
77. Joseph JR, Waguespack SG, Mahajan A, Puduvalli V, Fuller GN, McCutcheon IE. Pituitary carcinoma:experience from a single institution. American Association of Neurological Surgeons, Miami FL, April 14-18, 2012.

Book Chapters

1. Nassiri, F, Patil, V, Yefet, LS, Singh, O, Liu, J, Dang, RM, Yamaguchi, TN, Daras, M, Cloughesy, TF, Colman, H, Kumthekar, P, Chen, CC, Aiken, R, Groves, MD, Ong, SS, Ramakrishna, R, Vogelbaum, MA, Khagi, S, Kaley, T, Melear, JM, Peereboom, D, Rodriguez, A, Yankelevich, M, Nair, S, Puduvalli, VK, Aldape, KD, Gao, A, López-Janeiro, A, de Andrea, CE, Alonso, MM, Boutros, PC, Robbins, J, Mason, W, Sonabend, AM, Stupp, R, Fueyo-Margareto, J, Gomez-Manzano, C, Lang Jr, FF, Zadeh, G. Author Correction. In: Nature medicine, 3204, 2025.
2. Puduvalli, VK, Alnahhas, I, Giglio, P. Clinical Features, 986-992.e3, 2023.

Letters to the Editor

1. Gregory TA, Williford GL, Maronge JM, Alfaro K, Fuller GN, de Groot J, Puduvalli VK, Ballester LY, Majd NK. An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas. Neuro Oncol 25: 808-809, 2023.
2. Alnahhas, I, Rayi, A, Ong, SS, Giglio, P, Puduvalli, VK. Management of gliomas in patients with Lynch syndrome. Neuro-oncology 23: 167-168, 2021.
3. Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leuk Lymphoma 60: 2308-2311, 2019.
4. Kyritsis AP, Puduvalli VK, Levin VA. Chemotherapy as first line treatment for oligodendroglioma. J Neurooncol 86: 361-2, 2008.
5. Kyritsis AP, Tachmazoglou F, Rao JS, Puduvalli VK. Temozolomide and resistant glioma cells. J Neurosurg 108: 197; author reply 197-8, 2008.
6. Kyritsis AP, Rao JS, Puduvalli VK. Radio-responsive TRAIL gene therapy for malignant gliomas. Cancer Gene Ther 14: 1002, 2007.
7. Kyritsis AP, Rao JS, Puduvalli VK. Prognostic factors in multifocal gliomas: in regard to Showalter et al. (Int J Radiat Oncol Biol Phys 2007;69:820-824). Int J Radiat Oncol Biol Phys 69: 1335; author reply 1335, 2007.
8. Kyritsis AP, Tachmazoglou F, Rao JS, Puduvalli VK. Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clin Cancer Res 13: 6540-1; author reply 6541-2, 2007.

Web Publications

1. Sanchez, JR, Liu, C, Pawar, V, Huang, Y, Diaz-Rohena, DY, Singh, J, Koppikar, P, Lai, TH, St John, L, Puduvalli, VK, Molldrem, JJ, Thandapani, P, Jain, N, Lapalombella, R, Sampath, D. NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia, 2026.
2. Msherghi, A, Wong, FC, Xu, G, Mawlawi, O, Elhadi, M, Alsharedi, M, Salim, H, Alizada, S, Ray, WJ, Puduvalli, VK, Wintermark, M. 18F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients, 2025.
3. Garcia, CR, Highsmith, KN, Knight, SR, Andrade, IP, Leung, CH, Puduvalli, VK, Kamiya Matsuoka, C. Single center experience of IDH inhibitors in recurrent high-grade gliomas, 2025.
4. Morad, G, Damania, A, Melendez, B, Singh, BB, Veguilla, FJ, Soto, RA, Hoballah, YM, Sahasrabhojane, P, Wong, M, Ahmed, M, Rico, R, Lewis, KN, Wani, K, Shamsutdinova, D, Lazcano Segura, RN, Ingram, D, Goethe, E, Day, A, Flores, I, McDaniel, L, Chelvanambi, M, Johnson, S, Dimitriou, F, Gupta, P, Oberai, S, Zal, MA, Doss, P, Jamal, MA, Hayase, E, Wathoo, C, Norberg, L, Jenkins, SL, Nass, S, Gumin, J, Long, L, Yang, J, Bradley, GR, Bekal, MP, Dono, A, Pichardo-Rojas, PS, Andrewes, S, Ballester, L, Losh, JS, Liang, J, Huo, L, Nielsen, D, Parker Kerrigan, BC, Brastianos, PK, Fowlkes, NW, Chang, C, Jenq, RR, Gomez-Manzano, C, Huse, J, Davies, MA, Lazar, A, Bhat, KP, Tandon, N, Esquenazi, Y, Peterson, CB, Puduvalli, VK, Lang Jr, FF, Johnston, CD, Bullman, S, Ajami, NJ, Ferguson, SD, Wargo, J. Microbial signals in primary and metastatic brain tumors, 2025. PMCID: PMC12618227.
5. Majd, NK, Yeboa, DN, Wang, S, Weathers, S, Yuan, Y, Al Anssari, H, Kamiya Matsuoka, C, O'Brien, BJ, Aaroe, AE, Patel, C, Dagher, SA, Wintermark, M, Ferguson, SD, Puduvalli, VK, Liu, SJ, Raleigh, D, de Groot, JF. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma, 2024.